|Bid||75.72 x 800|
|Ask||75.99 x 800|
|Day's Range||75.04 - 75.78|
|52 Week Range||61.53 - 75.86|
|Beta (5Y Monthly)||0.31|
|PE Ratio (TTM)||25.36|
|Forward Dividend & Yield||1.84 (2.44%)|
|Ex-Dividend Date||Mar 26, 2021|
|1y Target Est||N/A|
PFE vs. NVO: Which Stock Is the Better Value Option?
For patients who go through the rigors of daily insulin shots to treat diabetes, the costs and logistics of adhering to a scheduled plan are a lot to keep up with. In 2020, two top healthcare companies performed admirably during phase 2 trials in a fight to help patients better manage diabetes. Novo Nordisk A/S (NYSE: NVO) and Eli Lilly (NYSE: LLY) both completed separate and successful phase 2 trials of new once-a-week insulin injection products that could potentially be game-changers in the insulin market for patients as well as investors.
NVO earnings call for the period ending March 31, 2021.